Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.61
AMRN's Cash to Debt is ranked higher than
62% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. AMRN: 0.61 )
AMRN' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.61

Equity to Asset -0.37
AMRN's Equity to Asset is ranked lower than
55% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AMRN: -0.37 )
AMRN' s 10-Year Equity to Asset Range
Min: -0.82   Max: 1
Current: -0.37

-0.82
1
F-Score: 3
Z-Score: -6.21
M-Score: -2.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -227.15
AMRN's Operating margin (%) is ranked higher than
50% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. AMRN: -227.15 )
AMRN' s 10-Year Operating margin (%) Range
Min: -6232.2   Max: 15.81
Current: -227.15

-6232.2
15.81
Net-margin (%) -108.97
AMRN's Net-margin (%) is ranked higher than
51% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. AMRN: -108.97 )
AMRN' s 10-Year Net-margin (%) Range
Min: -5384   Max: 16.15
Current: -108.97

-5384
16.15
ROA (%) -22.51
AMRN's ROA (%) is ranked higher than
55% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. AMRN: -22.51 )
AMRN' s 10-Year ROA (%) Range
Min: -549.69   Max: 10.46
Current: -22.51

-549.69
10.46
ROC (Joel Greenblatt) (%) -5981.89
AMRN's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. AMRN: -5981.89 )
AMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -41760.19   Max: -26.88
Current: -5981.89

-41760.19
-26.88
EBITDA Growth (3Y)(%) -31.50
AMRN's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AMRN: -31.50 )
AMRN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 85.5
Current: -31.5

0
85.5
EPS Growth (3Y)(%) -25.50
AMRN's EPS Growth (3Y)(%) is ranked higher than
58% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. AMRN: -25.50 )
AMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: -81.1   Max: 155.7
Current: -25.5

-81.1
155.7
» AMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AMRN Guru Trades in Q1 2014

Steven Cohen 610,313 sh (New)
Pioneer Investments 270,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

AMRN Guru Trades in Q2 2014

Jim Simons 184,200 sh (New)
Pioneer Investments 270,000 sh (unchged)
Steven Cohen 1,361,832 sh (unchged)
» More
Q3 2014

AMRN Guru Trades in Q3 2014

Paul Tudor Jones 13,438 sh (New)
Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q4 2014

AMRN Guru Trades in Q4 2014

Paul Tudor Jones 11,209 sh (-16.59%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Sold Out 0.08%$6.965 - $9.16 $ 1.54-81%0
John Burbank 2012-12-31 New Buy0.08%$7.68 - $12.6 $ 1.54-86%250000
George Soros 2012-09-30 Sold Out 0.06%$11.17 - $15.49 $ 1.54-89%0
George Soros 2012-06-30 New Buy0.06%$9.47 - $14.74 $ 1.54-86%300000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 5.92
AMRN's P/S is ranked higher than
67% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. AMRN: 5.92 )
AMRN' s 10-Year P/S Range
Min: 3.46   Max: 3720
Current: 5.92

3.46
3720
EV-to-EBIT -2.48
AMRN's EV-to-EBIT is ranked lower than
53% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. AMRN: -2.48 )
AMRN' s 10-Year EV-to-EBIT Range
Min: -221   Max: 0.5
Current: -2.48

-221
0.5
Current Ratio 4.47
AMRN's Current Ratio is ranked higher than
84% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. AMRN: 4.47 )
AMRN' s 10-Year Current Ratio Range
Min: 0.27   Max: 35.14
Current: 4.47

0.27
35.14
Quick Ratio 4.14
AMRN's Quick Ratio is ranked higher than
85% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. AMRN: 4.14 )
AMRN' s 10-Year Quick Ratio Range
Min: 0.22   Max: 35.14
Current: 4.14

0.22
35.14
Days Inventory 386.32
AMRN's Days Inventory is ranked higher than
56% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. AMRN: 386.32 )
AMRN' s 10-Year Days Inventory Range
Min: 54.08   Max: 650.68
Current: 386.32

54.08
650.68
Days Sales Outstanding 50.88
AMRN's Days Sales Outstanding is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. AMRN: 50.88 )
AMRN' s 10-Year Days Sales Outstanding Range
Min: 20.72   Max: 1521.32
Current: 50.88

20.72
1521.32

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.03
AMRN's Price/Median PS Value is ranked higher than
100% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. AMRN: 0.03 )
AMRN' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 12.04
Current: 0.03

0.01
12.04
Earnings Yield (Greenblatt) -40.30
AMRN's Earnings Yield (Greenblatt) is ranked lower than
52% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AMRN: -40.30 )
AMRN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 196.7   Max: 1906886
Current: -40.3

196.7
1906886

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:EH3A.Germany,
Amarin Corp PLC formerly Ethical Holdings plc is a public limited company incorporated under the laws of England and Wales. It was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993. The Company is a biopharmaceutical company having expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company's product Vascepa (icosapent ethyl) capsules is approved by the U.S. Food and Drug Administration for the use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (TG>500mg/dL) hypertriglyceridemia. On January 28, 2013 the Company commenced full commercial launch of Vascepa. The Company refers to its second indication for Vascepa as the ANCHOR indication. The FDA views the proposed ANCHOR indication as ostensibly and impliedly an indication to reduce cardiovascular risk. In addition, in December 2011, the Company announced commencement of patient dosing in cardiovascular outcomes study of Vascepa, titled REDUCE-IT or Reduction of Cardiovascular Events with EPA—Intervention Trial. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing cardiovascular events in a high risk patient population on statin therapy. The Company has over 6,500 patients enrolled in the REDUCE-IT study. The Company has pending supplemental new drug application, with the FDA that seeks marketing approval of Vascepa for use in the ANCHOR indication. Vascepa became commercially available in the United States by prescription in early 2013. On January 28, 2013, the Company commenced full commercial launch of Vascepa in the United States for use in the MARINE indication. The Company now markets Vascepa in the United States through sales force of approximately 150 sales professionals and also employed marketing and medical affairs personnel to support commercialization of Vascepa. As of February 1, 2014, over 16,000 clinicians had written prescriptions for Vascepa. In November 2010, the Company reported top-line data for the MARINE trial. Vascepa was well tolerated in the MARINE trial, with a safety profile comparable to placebo and there were no treatment-related serious adverse events observed. No significant changes in fasting blood glucose, hemoglobin A1C, vital signs, electrocardiograms, or liver or kidney function were observed with either Vascepa dose. The Company uses third party manufacturers and suppliers to manufacture clinical and commercial quantities of ethyl-EPA, which constitutes the only active pharmaceutical ingredient within Vascepa, to encapsulate, bottle and package Vascepa and to maintain inventory of Vascepa. The Company currently relies on Patheon for the encapsulation of Vascepa. The Companies competitors include GlaxoSmithKline plc and AbbVie, Inc., and Niaspan. The Company is subject to
» More Articles for AMRN

Headlines

Articles On GuruFocus.com
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 23 2014 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Steven Cohen Adds Amarin Corp. Awaiting Drug Approval, Buys Hyatt Hotels Mar 28 2012 
Soros Funds’ Great Britain Buys and Sells Apr 13 2011 


More From Other Websites
Amarin to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on... Mar 03 2015
Amarin to Report Fourth Quarter and Year-End 2014 Results and Host Conference Call on March 3, 2015 Mar 03 2015
Amarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations Mar 03 2015
Amarin Reports Fourth Quarter and Year-End 2014 Financial Results and Provides Update on Operations Mar 03 2015
Amarin to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on... Mar 02 2015
What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog Mar 02 2015
Intercept Pharmaceuticals (ICPT): Will It Miss Q4 Earnings? - Analyst Blog Feb 28 2015
Will Arena Pharmaceuticals (ARNA) Disappoint on Q4 Earnings? - Analyst Blog Feb 27 2015
Will Endo Internationa's (ENDP) Beat on Earnings in Q4? - Analyst Blog Feb 27 2015
Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog Feb 27 2015
Will Stratasys (SSYS) Disappoint this Earnings Season? - Analyst Blog Feb 27 2015
What Awaits Keryx Biopharmaceuticals (KERX) this Earnings? - Analyst Blog Feb 26 2015
Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa(R) (icosapent ethyl)... Feb 26 2015
Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa(R) (icosapent ethyl)... Feb 26 2015
Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog Feb 25 2015
Should You Buy Amarin Corporation (AMRN) Ahead of Earnings? - Tale of the Tape Feb 25 2015
Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Feb 24 2015
Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog Feb 24 2015
Will Ingram Micro (IM) Miss Earnings Estimates in Q4? - Analyst Blog Feb 24 2015
What's in Store for OmniVision (OVTI) This Earnings? - Analyst Blog Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK